A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: a prospective, randomised, double-blind, placebo-controlled trial
BJU International, 05/14/2012Tadros NN et al.
The authors found a 55% incidence of severe pain after ureteric stent removal. A single dose of a non–steroidal anti–inflammatory drug before stent removal prevents severe pain after ureteric stent removal.
A prospective, randomised, double-blind, placebo-controlled trial was performed at the authors institution.
Adults with an indwelling ureteric stent after ureteroscopy were randomised to receive either a single dose of placebo or an NSAID (rofecoxib 50 mg) before ureteric stent removal.
Pain was measured using a visual analogue scale (VAS) just before and 24 h after stent removal
Pain medication use after ureteric stent removal was measured using morphine equivalents.
In all, 22 patients were enrolled and randomised into the study before ending the study after interim analysis showed significant decrease in pain level in the NSAID group.
The most common indication for ureteroscopy was urolithiasis (14 patients).
The proportion of patients with severe pain (VAS score of ≥
7) during the 24 h after ureteric stent removal was six of 11 (55%) in the placebo group and it was zero of 10 in the NSAID group (P < 0.01).
There were no complications related to the use of rofecoxib.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.